step 1 trial semaglutide 2.4 mg weight loss nejm 2021 Long-term kidney outcomes of in obesity and cardiovascular disease in the SELECT FLOWing with the SemagluTIDE —

The development of glucagon-like peptide-1 (GLP-1) drugs for type 2 diabetes and obesity has brought hope to patients in terms of improving their health and quality of life

This is more noticeable in the first few weeks and usually indicates the peptide is working

Side Effect Overlap (Indirectly): While melatonin itself is generally well-tolerated, some people experience side effects like drowsiness, dizziness, or headache

The burping side effect is essentially a byproduct of the therapeutic action

Because the new research was observational, it cant prove the medications caused either condition

High-cost medical cases also added to the pressure